HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Clinical trials for HORMONE-RECEPTOR-POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HORMONE-RECEPTOR-POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HORMONE-RECEPTOR-POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill shows promise in shrinking Hard-to-Treat breast tumors
Disease control CompletedThis study tested a new oral drug called BGB-43395 in 33 Chinese patients with advanced or metastatic HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. The goal was to find a safe dose and see if it can shrink tumors wh…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New combo therapy for advanced breast cancer shows promise in early trial
Disease control CompletedThis early-phase study tested a new drug called ONO-4578 combined with standard hormone therapy and targeted drugs (letrozole plus palbociclib or abemaciclib) in 46 postmenopausal women with advanced or recurrent hormone receptor-positive, HER2-negative breast cancer. The main go…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New combo therapy shows promise for Hard-to-Treat breast cancer
Disease control CompletedThis early-phase study tested a combination of two drugs—capecitabine (a chemotherapy pill) and cemiplimab (an immunotherapy)—in 13 people with hormone receptor-positive breast cancer that had spread. The main goal was to find the safest dose and see if the combo could shrink tum…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Breast cancer drug showdown: which hormone therapy works better?
Disease control CompletedThis Phase 3 trial tested two hormone therapies, fulvestrant (Faslodex) and anastrozole (Arimidex), in 462 postmenopausal women with advanced hormone receptor-positive breast cancer who had not received prior hormone treatment. The study compared how long each drug kept the cance…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New drug combo offers hope for elderly breast cancer patients avoiding surgery
Disease control CompletedThis phase II trial tested a combination of hormone therapy drugs (fulvestrant or an aromatase inhibitor) plus palbociclib in 14 elderly patients with hormone-responsive breast cancer who either had inoperable tumors or were too frail for surgery. The goal was to see if this drug…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Can acupuncture cool hot flashes in breast cancer survivors?
Symptom relief CompletedThis study tested whether acupuncture can reduce hot flashes in women with hormone-positive breast cancer who are on hormonal therapy. 84 participants were randomly assigned to receive either acupuncture or usual care. The main goal was to see if acupuncture lowered hot flash sco…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Morning or evening? study tests best time for breast cancer pill to ease side effects
Symptom relief CompletedThis study looked at whether taking hormone therapy for breast cancer in the morning or evening reduces side effects and helps patients stay on treatment. 245 women with early-stage breast cancer were randomly assigned to take their medication either within an hour of waking or w…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE4 • Sponsor: Ottawa Hospital Research Institute • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
Can immunotherapy boost chemo for breast cancer? small study investigates
Knowledge-focused CompletedThis pilot study tested a combination of chemotherapy (Nab-Paclitaxel) and immunotherapy (Pembrolizumab) in 32 women with hormone receptor-positive, HER2-negative breast cancer before surgery. The main goal was to see how the treatment changed a biomarker called PD-L1 in tumor sa…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Adrienne G. Waks • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Real-world study examines quality of life and compliance in young breast cancer patients on hormone-blocking therapy
Knowledge-focused CompletedThis study involved 562 premenopausal women in China with hormone receptor-positive breast cancer who received a GnRHa injection to suppress ovarian function after surgery. Researchers measured their quality of life and how well they followed the treatment plan using questionnair…
Matched conditions: HORMONE-RECEPTOR-POSITIVE BREAST CANCER
Sponsor: Fudan University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC